Cargando…

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

INTRODUCTION: The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with the standard 10 mg/day dose. Results from this study indicated that afte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferris, Steven, Cummings, Jeffrey, Christensen, Daniel, Doody, Rachelle, Farlow, Martin, Sabbagh, Marwan, Liu, Liang, Mackell, Joan, Fain, Randi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055003/ https://www.ncbi.nlm.nih.gov/pubmed/23433097 http://dx.doi.org/10.1186/alzrt166

Ejemplares similares

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
por: Ferris, Steven H, et al.
Publicado: (2011)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
por: Sabbagh, Marwan, et al.
Publicado: (2016)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
por: Ferris, Steven, et al.
Publicado: (2013)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
por: Hong, Yun Jeong, et al.
Publicado: (2019)

Reliability and validity of the severe impairment battery in Taiwanese patients with moderate to severe Alzheimer’s disease
por: Huang, Mao-Hsuan, et al.
Publicado: (2020)

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
por: Chase, Thomas N., et al.
Publicado: (2017)

Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
por: Lang, Frederick M., et al.
Publicado: (2021)

A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia
por: Farlow, Martin R., et al.
Publicado: (2013)

Baseline Serum Estradiol Level Is Associated with Acute Kidney Injury in Patients with Moderately Severe and Severe Acute Pancreatitis
por: Pan, Jia-Jia, et al.
Publicado: (2022)

A Randomized Double-blind Study to Assess the Skin Irritation and Sensitization Potential of a Once-weekly Donepezil Transdermal Delivery System in Healthy Volunteers
por: Sabbagh, Marwan N., et al.
Publicado: (2023)

1490. Vancomycin 125 mg vs. 250 mg for the Treatment of Non-Severe and Severe Clostridium difficile Infections
por: Hsu, Amy, et al.
Publicado: (2019)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma
por: Khan, Asif H, et al.
Publicado: (2022)

Course of Cognitive Functioning in Institutionalized Persons With Moderate to Severe Dementia: Evidence From the Severe Impairment Battery Short Version
por: Wolf, Evelien T., et al.
Publicado: (2018)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
por: Thyssen, Jacob P., et al.
Publicado: (2023)

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
por: Atri, Alireza, et al.
Publicado: (2015)

The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain
por: Parsons, Bruce, et al.
Publicado: (2019)

Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia
por: Bashkin, Amir, et al.
Publicado: (2022)

Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer’s patients in long-term care health facilities
por: Meguro, Kenichi, et al.
Publicado: (2014)

Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
por: Rasi, Abbas, et al.
Publicado: (2014)

Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment
por: Karaoui, Lamis R., et al.
Publicado: (2018)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

A cause of severe thigh injury: Battery explosion
por: Görgülü, Tahsin, et al.
Publicado: (2015)

Randomized clinical trial of dexketoprofen/tramadol 25 mg/75 mg in moderate-to-severe pain after total hip arthroplasty
por: McQuay, H. J., et al.
Publicado: (2016)

Baseline Body Composition in Prepubertal Short Stature Children with Severe and Moderate Growth Hormone Deficiency
por: Matusik, Pawel, et al.
Publicado: (2016)

Prediction of moderately severe and severe acute pancreatitis in pregnancy: Several issues
por: Yang, Qun-Ying, et al.
Publicado: (2022)

A Randomized, Crossover, Single-Dose Bioequivalence Study of Two Extended-Release Tablets of Donepezil 23 mg in Healthy Human Volunteers under Fasting and Fed States
por: Gadiko, Chaitanya, et al.
Publicado: (2013)

The severity of microstrokes depends on local vascular topology and baseline perfusion
por: Schmid, Franca, et al.
Publicado: (2021)

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease
por: Farlow, Martin R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kfj7ou25ah3ev2p7id2iesgh52